SCHEMBL2432941

SCHEMBL2432941

CC(Cc1ccc(OCc2cc(Br)cc3c2OC(C)(C)C3)cc1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.43
MAOB P27338 3/20 0.39
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
FFAR4 Q5NUL3 3/20 0.37
GYS1 P13807 1/20 0.37
PPARG P37231 3/20 0.37
PPARA Q07869 4/20 0.37
PPARD Q03181 3/20 0.37
KDM5A P29375 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KMT2A Q03164 1/20 0.36
ITGB1 P05556 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2436885 0.89 MAOB (0.38) FFAR1MAOBKDM4ENPC1ALDH1A1
SCHEMBL2432792 0.89 GYS1 (0.44) FFAR1MAOBFFAR4GYS1PPARG
SCHEMBL2432789 0.89 GYS1 (0.44) FFAR1MAOBFFAR4GYS1PPARG
SCHEMBL3000273 0.89 GYS1 (0.44) FFAR1MAOBFFAR4GYS1PPARG
SCHEMBL2432028 0.89 FFAR1 (0.46) FFAR1MAOBFFAR4GYS1PPARG
SCHEMBL12036486 0.88 FFAR1 (0.43) FFAR1MAOBKDM4EHTTSMN1; SMN2
SCHEMBL12036487 0.88 FFAR1 (0.43) FFAR1MAOBKDM4EHTTSMN1; SMN2
SCHEMBL2431868 0.88 FFAR1 (0.43) FFAR1MAOBKDM4EHTTSMN1; SMN2
SCHEMBL12036104 0.88 FFAR4 (0.49) FFAR1MAOBFFAR4PPARAPPARD
SCHEMBL9983534 0.85 PTGER4 (0.41) FFAR1FFAR4GYS1PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582674-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2013-04-24 EP claimed
EP-2367793-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX INC (US) 2013-03-27 EP claimed
US-8309600-B2 GPR120 receptor agonists and uses thereof METABOLEX INC. (US) 2012-11-13 US claimed
WO-2011159297-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-22 WO claimed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 US claimed
EP-2367793-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-09-28 EP claimed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US claimed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO claimed
EP-2582674-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF CYMABAY THERAPEUTICS INC (US) 2014-10-01 EP disclosed
EP-2582674-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF CYMABAY THERAPEUTICS INC (US) 2014-10-01 EP disclosed
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2014-05-01 US disclosed
US-8598374-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-12-03 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
EP-2367793-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-09-28 EP disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR FFAR1 22/4885MAOB 3960/4885KDM4E 4479/4885
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR FFAR1 22/4885MAOB 3960/4885KDM4E 4479/4885
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR FFAR1 22/4885MAOB 3960/4885KDM4E 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.